A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults

NCT07749651 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

50

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Lupus Erythematosus(CLE)

Interventions

DRUG: SHR-7012 injection ; placebo
DRUG: SHR-7012 injection ; placebo
DRUG: SHR-7012 injection ; placebo
DRUG: SHR-7012 injection ; placebo
DRUG: SHR-7012 injection ; placebo ;

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd